WINTON GROUP Ltd Buys 1,274 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

WINTON GROUP Ltd boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 24.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,565 shares of the company’s stock after buying an additional 1,274 shares during the quarter. WINTON GROUP Ltd’s holdings in Krystal Biotech were worth $1,028,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Krystal Biotech by 9.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after buying an additional 19,777 shares in the last quarter. Citigroup Inc. boosted its stake in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after acquiring an additional 13,874 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Krystal Biotech by 346.8% in the third quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company’s stock worth $1,899,000 after purchasing an additional 8,098 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Krystal Biotech by 3.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock worth $840,000 after purchasing an additional 153 shares during the period. Finally, Edgestream Partners L.P. bought a new position in shares of Krystal Biotech during the third quarter valued at approximately $5,872,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Stock Performance

KRYS opened at $183.92 on Friday. The company’s 50-day simple moving average is $170.82 and its two-hundred day simple moving average is $173.73. The stock has a market capitalization of $5.30 billion, a P/E ratio of 61.51 and a beta of 0.87. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the firm earned $0.30 earnings per share. The firm’s revenue for the quarter was up 116.4% compared to the same quarter last year. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).